AtheroGenics Drops AGIX-4207 After Failed Rheumatoid Arthritis Phase II Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AtheroGenics will discontinue development of its rheumatoid arthritis therapy AGIX-4207 following an unsuccessful Phase II trial.